Medovert (Cinnarizine, Dimenhydrinate)

Cinnarizine blocks calcium channels in the vestibular system, reducing excitability that contributes to dizziness. Dimenhydrinate antagonizes peripheral and central H1 histamine receptors, diminishing the histamine‑mediated signals that trigger nausea and vomiting. Together they provide complementary anti‑vertigo and anti‑emetic effects.

The dosage of Medovert is individualized by the prescribing clinician based on the patient’s age, condition severity and response to therapy. Healthcare professionals determine the appropriate strength, frequency and duration of treatment, and patients should follow the prescribed regimen exactly.

Safety data for cinnarizine and dimenhydrinate in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy or breastfeeding should discuss alternatives with their healthcare provider.

To order Medovert, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Medovert combines a calcium‑channel blocker (cinnarizine) with an H1‑antihistamine (dimenhydrinate), offering both vestibular stabilization and antihistamine effects. Compared with single‑agent drugs such as meclizine, Medovert may provide broader symptom control for vertigo and motion sickness, though individual response and tolerability vary.

Store Medovert at ambient temperature, preferably below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Medovert is taken orally, usually with a glass of water. It can be taken with or without food, unless the prescribing clinician advises otherwise. Swallow the tablet whole; do not crush or chew unless instructed by a healthcare professional.

Serious adverse reactions, although rare, include extrapyramidal symptoms such as involuntary muscle movements, severe allergic responses (e.g., anaphylaxis, skin rash), hepatic dysfunction, cardiac arrhythmias, and blood‑cell abnormalities. Patients should seek immediate medical attention if they experience any of these symptoms.

Medovert is contraindicated in individuals with known hypersensitivity to cinnarizine, dimenhydrinate or any excipients in the formulation. It should be avoided in patients with severe hepatic impairment, uncontrolled epilepsy, or those taking medications that may cause dangerous additive sedation or anticholinergic effects without medical supervision.